File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Novel systemic therapy for hepatocellular carcinoma

TitleNovel systemic therapy for hepatocellular carcinoma
Authors
KeywordsAccelerated approval
Adverse events
Anti-angiogenesis
Combination therapy
Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)
Issue Date2020
PublisherSpringer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072
Citation
Hepatology International, 2020, v. 14 n. 5, p. 638-651 How to Cite?
AbstractSystemic therapy for hepatocellular carcinoma (HCC) used to be limited to patients with advanced diseases and multi-kinase inhibitors targeting tumor angiogenesis the major approach of developing new treatment options. In the past 3 years, new data from trials of both molecular targeted therapy and immune checkpoint inhibitors (ICI) provided many new options of first- and second-line treatment for advanced HCC. Most notably, combination of ICI targeting the program cell death-1 (PD-1) pathway with other novel agents or conventional anti-cancer therapy may further improve treatment efficacy in different clinical settings. In this paper updated data of clinical trials of systemic therapy in the first- and second-line settings for advanced HCC were reviewed and the following issues were discussed: (1) lessons of trial design learned from positive and negative trials; (2) the balance between efficacy and safety in clinical practice; and (3) impact on future multi-disciplinary management of HCC.
Persistent Identifierhttp://hdl.handle.net/10722/305382
ISSN
2023 Impact Factor: 5.9
2023 SCImago Journal Rankings: 1.813
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorDong, Y-
dc.contributor.authorLiu, TH-
dc.contributor.authorYau, T-
dc.contributor.authorHsu, C-
dc.date.accessioned2021-10-20T10:08:37Z-
dc.date.available2021-10-20T10:08:37Z-
dc.date.issued2020-
dc.identifier.citationHepatology International, 2020, v. 14 n. 5, p. 638-651-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/305382-
dc.description.abstractSystemic therapy for hepatocellular carcinoma (HCC) used to be limited to patients with advanced diseases and multi-kinase inhibitors targeting tumor angiogenesis the major approach of developing new treatment options. In the past 3 years, new data from trials of both molecular targeted therapy and immune checkpoint inhibitors (ICI) provided many new options of first- and second-line treatment for advanced HCC. Most notably, combination of ICI targeting the program cell death-1 (PD-1) pathway with other novel agents or conventional anti-cancer therapy may further improve treatment efficacy in different clinical settings. In this paper updated data of clinical trials of systemic therapy in the first- and second-line settings for advanced HCC were reviewed and the following issues were discussed: (1) lessons of trial design learned from positive and negative trials; (2) the balance between efficacy and safety in clinical practice; and (3) impact on future multi-disciplinary management of HCC.-
dc.languageeng-
dc.publisherSpringer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072-
dc.relation.ispartofHepatology International-
dc.rightsAccepted Manuscript (AAM) This is a post-peer-review, pre-copyedit version of an article published in [insert journal title]. The final authenticated version is available online at: https://doi.org/[insert DOI]-
dc.subjectAccelerated approval-
dc.subjectAdverse events-
dc.subjectAnti-angiogenesis-
dc.subjectCombination therapy-
dc.subjectCytotoxic T-lymphocyte-associated protein-4 (CTLA-4)-
dc.titleNovel systemic therapy for hepatocellular carcinoma-
dc.typeArticle-
dc.identifier.emailYau, T: tyaucc@hku.hk-
dc.identifier.authorityYau, T=rp01466-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s12072-020-10073-7-
dc.identifier.pmid32661949-
dc.identifier.scopuseid_2-s2.0-85089032113-
dc.identifier.hkuros326653-
dc.identifier.volume14-
dc.identifier.issue5-
dc.identifier.spage638-
dc.identifier.epage651-
dc.identifier.isiWOS:000548444900001-
dc.publisher.placeIndia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats